Newsmv

PharmAla Biotech Signs $100 Million-Plus Term Sheet to License ALA-002 MDMA Therapeutic to Jupiter Neurosciences

6/23/2026

PharmAla Biotech has signed a term sheet granting Jupiter Neurosciences, Inc. licensing rights to ALA-002, its next-generation MDMA therapeutic, in a transaction valued at over $100 million.

The agreement positions the Nasdaq-listed Jupiter Neurosciences as PharmAla's designated U.S. partner for the MDMA-based drug candidate.

At over $100 million, the deal's stated valuation signals the commercial weight both parties are assigning to ALA-002's prospects in the American market.

ALA-002: PharmAla's Next-Generation MDMA Therapeutic ALA-002 is PharmAla Biotech's next-generation MDMA therapeutic and the compound at the center of the Jupiter Neurosciences arrangement.